

< Back to results | < Previous 7 of 34 Next >

Export Download Print E-mail Save to PDF Add to List More... >

Latin American Journal of Pharmacy
Volume 36, Issue 7, 2017, Pages 1462-1468

A validated stability indicating high performance liquid chromatographic method for Olanzapine (Article)

Rakibe, U.^a, Rane, V.^b, Yeole, R.^b, Afnan, A.^c, Wakte, P.^a

^aDepartment of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, MS 431004, India

^bWockhardt Research Centre, Aurangabad, MS 431006, India

^cStep Change Pharma Inc., Metro Area, Washington, DC, United States

Abstract

View references (17)

The present study describes the development and validation of isocratic stability indicating reversed phase high performance liquid chromatographic (HPLC) method for olanzapine (OLZ). An Alltima Cyano (250.0 × 4.6 mm, 5 μm) column and acetate buffer (pH 4.5) and acetonitrile (40:60 v/v) as a mobile phase were used. The detection was carried out at the wavelength of 254 nm. OLZ was subjected to various stress conditions. Degradation was observed for OLZ in acid, base, oxidative, heat conditions and stable in other stress conditions. The proposed method could able to separate OLZ from the known impurity and degradation products. The developed method was validated as per ICH guideline Q2(R1). The specificity of the method proved from forced degradation studies as the stability indicating power of the method. The developed HPLC method can be used in quality control and stability sample analysis of OLZ. © 2017, Colegio de Farmaceuticos de la Provincia de Buenos Aires. All rights reserved.

SciVal Topic Prominence

Topic: Clozapine | Antipsychotic Agents | therapeutic drug

Prominence percentile: 81.905

Reaxys Database Information

View Compounds

Author keywords

Forced degradation Liquid chromatography Olanzapine Stability indicating

Indexed keywords

EMTREE drug terms: olanzapine

EMTREE medical terms:

analytical parameters Article drug selectivity drug solubility drug specificity
drug stability forced degradation study high performance liquid chromatography human
limit of detection limit of quantitation linearity measurement accuracy
measurement precision mental disease quality control schizophrenia validation process

Chemicals and CAS Registry Numbers:

olanzapine, 132539-06-1

Drug tradename:

zyprax

Metrics

0 Citations in Scopus

0 Field-Weighted
Citation Impact



PlumX Metrics

Usage, Captures, Mentions,
Social Media and Citations
beyond Scopus.

Cited by 0 documents

Inform me when this document
is cited in Scopus:

Set citation alert >

Set citation feed >

Related documents

Identification and
characterization of olanzapine
degradation products under
oxidative stress conditions

Hirianna, S.G. , Basavaiah, K. ,
Goud, P.S.K.
(2008) *Acta Chromatographica*

Development of a simple and
stability-indicating RP-HPLC
method for determining
olanzapine and related impurities
generated in the preparative
process

Cui, D. , Li, Y. , Lian, M.
(2011) *Analyst*

Determination of olanzapine in
human plasma by reversed-phase
high-performance liquid
chromatography with ultraviolet
detection

D'Arrigo, C. , Migliardi, G. ,
Santoro, V.
(2006) *Therapeutic Drug
Monitoring*

View all related documents based
on references

Find more related documents in
Scopus based on:

Authors > Keywords >

References (17)

[View in search results format >](#)

All Export Print E-mail Save to PDF Create bibliography

-
- 1 Bhana, N., Foster, R.H., Olney, R., Plosker, G.L.
Olanzapine: An updated review of its use in the management of schizophrenia

(2001) *Drugs*, 61 (1), pp. 111-161. Cited 171 times.
<http://rd.springer.com/journal/40265>
doi: 10.2165/00003495-200161010-00011

[View at Publisher](#)
-
- 2 Maloney, A.E., Sikich, L.
(2010) *Neuropsychiatr. Dis. Treat.*, 6, pp. 749-766. Cited 16 times.
-
- 3 Dusci, L.J., Peter Hackett, L., Fellows, L.M., Ilett, K.F.
Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection

(2002) *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, 773 (2), pp. 191-197. Cited 73 times.
doi: 10.1016/S1570-0232(02)00164-2

[View at Publisher](#)
-
- 4 Olesen, O.V., Linnert, K.
Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs

(1998) *Journal of Chromatography B: Biomedical Applications*, 714 (2), pp. 309-315. Cited 86 times.
doi: 10.1016/S0378-4347(98)00205-9

[View at Publisher](#)
-
- 5 Chiu, J.A., Franklin, R.B.
Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection

(1996) *Journal of Pharmaceutical and Biomedical Analysis*, 14 (5), pp. 609-615. Cited 60 times.
www.elsevier.com/locate/jpba
doi: 10.1016/0731-7085(95)01651-1

[View at Publisher](#)
-
- 6 Catlow, J.T., Barton, R.D., Clements, M., Gillespie, T.A., Goodwin, M., Swanson, S.P.
Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection

(1995) *Journal of Chromatography B: Biomedical Sciences and Applications*, 668 (1), pp. 85-90. Cited 114 times.
doi: 10.1016/0378-4347(95)00061-M

[View at Publisher](#)
-

- 7 Bogusz, M.J., Krüger, K.D., Maier, R.D., Erkwoh, R., Tuchtenhagen, F.
Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry
(1999) *Journal of Chromatography B: Biomedical Sciences and Applications*, 732 (2), pp. 257-269. Cited 68 times.
doi: 10.1016/S0378-4347(99)00287-X
[View at Publisher](#)
-
- 8 Larew, L.A., Olsen, B.A., Stafford, J.D., Wilhelm, M.V.
Comparison of theory-based and empirical modeling for the prediction of chromatographic behavior in the ion-pairing separation of benzodiazepine-derived pharmaceutical compounds
(1995) *Journal of Chromatography A*, 692 (1-2), pp. 183-193. Cited 11 times.
doi: 10.1016/0021-9673(94)00877-C
[View at Publisher](#)
-
- 9 Raggi, M.A., Casamenti, G., Mandrioli, R., Izzo, G., Kenndler, E.
Quantitation of olanzapine in tablets by HPLC, CZE, derivative spectrometry and linear voltammetry
(2000) *Journal of Pharmaceutical and Biomedical Analysis*, 23 (6), pp. 973-981. Cited 75 times.
doi: 10.1016/S0731-7085(00)00382-4
[View at Publisher](#)
-
- 10 Basavaiah, K., Rangachar, A.K.U., Tharpa, K.
Quantitative determination of olanzapine in pharmaceutical preparations by HPLC
(2008) *Journal of the Mexican Chemical Society*, 52 (2), pp. 120-124. Cited 8 times.
<http://www.jmcs.org.mx/PDFS/V52/2/04-Quantitative.pdf>
-
- 11 Hussien, L.A.E.A., Ghani, M.F.A., El-Alamein, A.M.A., Mohamed, E.H.
(2014) *Eur J. Chem*, 5, pp. 311-320.
-
- 12 Baertschi, S.W., Brunner, H., Bunnell, C.A., Cooke, G.G., Diseroad, B., Dorman, D.E., Jansen, P.J., (...), Speakman, J.L.
Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations
(2008) *Journal of Pharmaceutical Sciences*, 97 (2), pp. 883-892. Cited 18 times.
www.interscience.wiley.com/jpages/0022-3549
doi: 10.1002/jps.21146
[View at Publisher](#)
-
- 13 Hiriyanna, S.G., Basavaiah, K., Goud, P.S.K., Dhayanithi, V., Raju, K., Pati, H.N.
Identification and characterization of olanzapine degradation products under oxidative stress conditions
(2008) *Acta Chromatographica*, (20), pp. 81-93. Cited 22 times.
doi: 10.1556/ACHrom.20.2008.1.7
[View at Publisher](#)
-
- 14 (2003) *Stability Testing of New Drug Substance and Products*. Cited 8 times.
Q1A (R2)
-
- 15 (1998) *Stability Testing of New Drug Substance and Products*
Q1B

About Scopus

[What is Scopus](#)
[Content coverage](#)
[Scopus blog](#)
[Scopus API](#)
[Privacy matters](#)

Language

[日本語に切り替える](#)
[切换到简体中文](#)
[切换到繁體中文](#)
[Русский язык](#)

Customer Service

[Help](#)
[Contact us](#)

ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

Copyright © 2018 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

 RELX Group™